HBV Treatment
IAS 2013: Many People Need Hepatitis B Treatment in the Gambia
- Details
- Category: HBV Treatment
- Published on Monday, 15 July 2013 00:00
- Written by Liz Highleyman
About 8% of people tested through a community-based screening program in the Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.
DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?
- Details
- Category: HBV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
Coverage of Digestive Disease Week 2013
- Details
- Category: HBV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.
Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.
HIVandHepatitis.com DDW 2013 conference section
5/22/13
DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Wednesday, 08 May 2013 00:00
- Written by Liz Highleyman
Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress(EASL 2013) last month in Amsterdam. The study also showed that early hepatitis B surface antigen (HBsAg) decline is a predictor of treatment response in some patients.
More Articles...
- EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?
- Coverage of the 2013 EASL International Liver Congress
- EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
Web Design and Development by